– First CRISPR gene-editing filings to be accepted for review by FDA – – FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT) – – PDUFA target action date of December 8, 2023 , for SCD and March 30, 2024 , for TDT –
– First CRISPR gene-editing filings to be accepted for review by FDA – – FDA grants Priority Review for severe sickle cell disease (SCD) and…
– Both trials met the primary and key secondary endpoints at the pre-specified interim analysis – – Data continue to demonstrate transformative and durable benefit…
– First CRISPR gene-editing filings to be accepted for review by FDA – – FDA grants Priority Review for severe sickle cell disease (SCD) and…
-Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)-…
The Theme May 8, 2023 is International Thalassaemia Day. The theme of the event this year is “Strengthening Education to Bridge the Thalassaemia Care Gap”.…
The Investor Relations website contains information about CRISPR Therapeutics’s business for stockholders, potential investors, and financial analysts.
-EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023- BOSTON and…
ZUG, Switzerland and BOSTON , March 14, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious…
ZUG, Switzerland and BOSTON , March 13, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for…
